Diabetes Day for Primary Care Providers

Louisville, KY

Vertical Tabs

Overview

With an aging population and longer life expectancy come an increased prevalence of chronic diseases and conditions, including diabetes. The percentage of United States adults with diabetes (including both diagnosed and undiagnosed) is at least 8.3% (based on 2010 numbers), far exceeding the capacity of the specialists, the endocrinologists, to manage these patients. For example, each year there are more than 28 million ambulatory care visits with diabetes as primary diagnosis.

The vast majority of patients with type 2 diabetes are managed in the primary care setting. Primary care clinicians need to accept the challenge to more aggressively treat their patients with diabetes.  This can help patients reach optimal glycemic goals, reduce the burden of the disease, and improve the patient’s health outcomes and quality of life. As the recognized experts on this metabolic condition, endocrinologists are the content experts and lead authorities in diabetes clinical research and its application to clinical practice. Therefore, they are uniquely qualified to provide continuing education regarding diabetes and its care to primary care physicians.

More effective education for primary care physicians and clinicians can help improve cardiometabolic control in patients with diabetes. With more knowledge, primary care physicians can more effectively educate their patients about the disease and the value of preventive therapy. Awareness of barriers, identification of strategies to overcome obstacles, and further opportunities for practitioners to problem-solve strategies to assist patients in managing a chronic illness that requires numerous daily decisions are all needed.

The program will comprehensively address the complex challenges faced by primary care providers in the areas of diabetes prevention, diagnosis, and treatment, as well as co-morbid conditions that make diabetes such a complex disease. The education will provide an in-depth look at current guidelines, clinical thinking, and management practices to successfully treat diabetes and modifiable cardiometabolic issues. An ethnically and clinically-diverse patient population will also be used to develop interactive “real patient-case” vignettes to help learners better understand the real-world challenges and cultural health disparities of patients with diabetes, as well as how to best address their care.

Target Audience

Primary care providers including MDs, DOs, NPs, PAs, RNs, CDEs, Pharmacists and other interested health care providers.

Agenda
7:00 am - 8:00 am       Registration - Exhibit Hall Open
     
8:00 am - 8:10 am   Welcome Remarks & Objectives Review
    Vasdev Lohano, MD, FACE – Local Program Chair
     
8:10 am - 8:35 am   Type 2 Diabetes and Obesity Epidemic: 
    Pathophysiology, Diagnosis and Treatment Goals
    Vasdev Lohano, MD, FACE – Local Program Chair
     
8:35 am - 8:45 am   Q&A
     
8:45 am - 9:15 am   Treatment of Type 2 Diabetes: What Have We Learned?
    Jahangir Cyrus, MD, FACE
     
9:15 am -  9:25 am   Q&A
     
9:25 am - 9:50 am   Addressing the Incretin Defect in Treatment of Type 2 Diabetes
    Sri Prakash Mokshagundam, MD
     
9:50 am - 10:00 am   Q&A
     
10:00 am - 10:30 am   Break – Exhibit Hall Open
     
10:30 am - 11:00 am   Cardiovascular Risk Reduction and Other Co-Morbidities in Type 2 Diabetes
    Sathya Krishnasamy, MD
     
11:00 am - 11:10 am   Q&A
     
11:10 am - 11:45 am   Insulin Initiation and Intensification
    Lal Tanwani, MD, FACE
     
11:45 am - 11:55 am   Q&A
     
11:55 am - 12:20 pm   Education & Lifestyle
    Beth Ackerman, MS, RD, CDE
     
12:20 pm - 12:30 pm   Q&A
     
12:30 pm  -  1:00 pm   Case Presentation: Management of Diabetes, Applying Science to Practice
    All Faculty
     
1:00 pm   Adjourn
Educational Objectives
After participating in the continuing education program, participants will have an improved ability to:
  • Describe the different methods available to diagnose type 2 diabetes.
  • Select appropriate classes of therapeutic agents designed to treat specific diabetic pathophysiologic defects.
  • Identify patients at risk for prediabetes and diabetes.
  • Implement strategies to reduce the risk of adverse outcomes for prediabetes and diabetes patients by meeting treatment goals for glucose, lipids, and blood pressure.
  • Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1c lowering needed, patient specific concerns, adverse effects, comorbidities, and contraindications.
  • Discuss the role of combination therapy and when it should be initiated based on A1c goals.
  • Explain the implications of recent clinical trials and meta-analyses on clinical practice decisions.
  • State the modes of action and clinical potential of therapeutic agents, including amylin agonists, incretin-based therapies, and other more recently introduced agents in the management of patients with type 2 diabetes.
  • Differentiate new and traditional treatment strategies with respect to factors, such as A1c lowering potential, route of administration, effects on weight and/or CV risk, including whether or not they can be used as part of mono- or combination-therapy strategies.
  • Describe the relationship between major CV risk factors and CVD outcomes.
  • Select therapeutic modalities available to practitioners to improve the CV risk factors.
  • Recognize the implications of recent large trials on clinical decisions guiding choice and targets for blood pressure and lipid abnormalities.
  • Discuss other co-morbid/microvascular conditions associated with type 2 diabetes patients.
  • Select strategies how to introduce insulin to patients who are candidates for this therapy.
  • Differentiate human insulin and insulin analogs from each other, including pharmacokinetics, predictability, incidence of hypoglycemia, weight gain, and patient administration.
  • Describe how to intensify an insulin regimen as needed to achieve glycemic targets.
  • Examine available insulin modalities (vials, devices) for delivery and their use in the outpatient setting.
  • List approaches to incorporate patient education in self-management treatment methods.
  • Develop strategies to involve other healthcare professionals to support the care of patients with type 2 diabetes.
  • State the activity and nutritional recommendations for patients with type 2 diabetes.
  • Summarize steps on how to apply the knowledge gained from this activity to the learners practice to improve and document the disease management outcomes for patients with type 2 diabetes.
Faculty

Vasdev Lohano, MD, FACE 

Local Program Chair

Joslin Diabetes Center at Floyd Memorial Hospital

New Albany, IN

 

 

Jahangir Cyrus, MD, FACE

 BMA Endocrinology, Attending Endocrinologist

Louisville, KY  

 

 

Sathya Krishnasamy, MD

 Associate Professor of Medicine, University of Louisville School of Medicine

Louisville, KY

 

 

Sri Prakash Mokshagundam, MD

Associate Professor, Division of Endocrinology and Metabolism, University of Louisville

Chief, Endocrinology Section, Louisville VA Medical Center

 Louisville, KY

Endocrinologist, Joslin Diabetes Center at Floyd Memorial Hospital

New Albany, IN

 

 

Lal Tanwani, MD, FACE

Private Practice

Louisville, KY 

 

 

Beth Ackerman, MS, RD, CDE

Program Coordinator, Joslin Diabetes Center Affiliate

at Floyd Memorial Hospital and Health Services

 

 

 

Steering/Program Committee

Chair - George Grunberger, MD, FACP, FACE

Chairman, Grunberger Diabetes Institute

Clinical Professor, Internal Medicine and Molecular Medicine & Genetics

Wayne State University School of Medicine

 

 

Vice Chair - Alan J. Garber, MD, PhD, FACE

Professor Departments of Medicine,

Biochemistry and Molecular Biology and Molecular and Cellular Biology

Baylor College of Medicine

Houston, TX

 

 

Ex Officio, AACE President - Jeffrey I. Mechanick, MD, FACP, FACE, FACN, ECNU

Clinical Professor of Medicine

Director, Metabolic Support

Division of Endocrinology, Diabetes, and Bone Disease, Mount Sinai School of Medicine

New York, NY

 

 

Ex Officio, Chair, Council on Education - Pasquale J. Palumbo, MD, MACP, MACE

Professor of Medicine, Mayo Clinic College of Medicine

Scottsdale, AZ

 

 

David S. H. Bell, MD, MB, FACP, FACE

Adjunct Clinical Professor of Medicine University of Alabama Medical School  

Birmingham, AL

Director, Southside Endocrinology

Mountain Brook, AL 

 

 

Felice A. Caldarella, MD, FACP, CDE, FACE

Research Director, Diabetes and Endocrine Associates of Hunterdon

Hunterdon Medical Center  

 

 

Chris K. Guerin, MD, FACE, FNLA

Assistant Clinical Professor of Medicine University of California

San Diego, CA

 

 

Yehuda Handelsman, MD, FACP, FACE, FNLA

Medical Director, Metabolic Institute of America 

Tarzana, CA  

 

 

Jennifer Hone, MD, FACE  

Director of Diabetes Programs, American Indian Health & Services

Santa Barbara, CA 

 

 

Daniel L. Hurley, MD, FACE

Assistant Professor of Medicine, Mayo Medical School

Consultant, Division of Endocrinology and Metabolism, Mayo Clinic

Rochester, MN 

 

 

Bethany A. Jackson, MD

Endocrine Fellow, Medical College of Georgia, Georgia Regents University

Augusta, GA 

 

 

Armand A. Krikorian, MD, FACE

Internal Medicine Residency Program Director, Advocate Christ Medical Center

Oak Lawn, IL

 

 

Etie S. Moghissi, MD, FACP, FACE

Clinical Associate Professor, University of California Los Angeles

 

 

Fernando Ovalle, MD, FACE

Professor of Medicine, Director, Diabetes and Glycemic Control Programs at UAB

University of Alabama at Birmingham School of Medicine

Birmingham, AL

 

 

Jill M. Paulson, MD, ECNU

Rockville Internal Medicine Group, Endocrinology

Rockville, MD 

 

 

Paul D. Rosenblit, MD, FACE

Clinical Professor, Medicine (Division of Endocrinology, Diabetes, Metabolism)

University California, Irvine (UCI), School of Medicine

Irvine, CA

Co-Director Diabetes Out-Patient Clinic, UCI Medical Center

 Orange, CA

Director, Diabetes/Lipid Management & Research Center

Huntington Beach, CA

 

 

Cheryl R. Rosenfeld, DO, FACP, FACE

Clinical Assistant Professor of Medicine, NYIT College of Osteopathic Medicine

Old Westbury, NY

Adjunct Clinical Assistant Professor of Medicine, Touro College of Osteopathic Medicine

New York, NY

North Jersey Endocrine Consultants

Denville, NJ

 

 

Stanley S. Schwartz, MD, FACE

Affiliate Main Line Health System

Emeritus, Clinical Associate Professor of Medicine

University of Pennsylvania 

 

 

Elliot Sternthal, MD, FACP, FACE

Assistant Professor of Medicine, Boston University School of Medicine

 

 

Nancy S. Tarlin, MD, FACP, FACE

Co-Director Endocrinology, Elmhurst Hospital

Elmhurst, NY

Assistant Professor Medicine, Mount Sinai School of Medicine 

 

 

Joseph M. Tibaldi, MD, FACP, FACE

Queens Diabetes and Endocrinology Associates

Assistant Clinical Professor of Medicine, Weill Cornell Medical College 

 

 

Jeff Unger, MD

Director, Metabolic Studies, Catalina Research Institute

Director, Unger Primary Care Medical Center

 

 

Disclosure

PIM Disclosure Summary:

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP; and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

 

 

 

Declaration of Disclosure and Conflicts of Interest:

It is the policy of AACE to ensure balance, independence, objectivity, and scientific rigor in all of its CME activities.  Presentation content may include discussion of an unlabeled use of a commercial product or an investigational use of a product not yet approved for any purpose.  AACE requires that participating faculty disclose to the audience any product(s) and its use(s) discussed in the educational activity that are unapproved/unlabeled for the use by the FDA or still considered investigational in nature. 

 

Everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships. “Relevant financial relationships” are financial relationships in any amount occurring within the past 12 months that create a conflict of interest.  AACE requires speakers, faculty, CME Committee, and other individuals who are in a position to control the content of this educational activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity.  All identified conflicts of interest are thoroughly evaluated by AACE for fair balance, scientific objectivity of studies mentioned in the presentation, and educational materials used as basis for content, and appropriateness of patient care recommendations. 

 

The intent of this disclosure is not to prevent a speaker with commercial affiliations from presenting, but rather to provide learners with information from which they may make their own judgments.  Informed learners are the final safeguards in assuring that a CME activity is independent from commercial influence. 

 

 AACE has reviewed all disclosures and resolved or managed all identified conflicts of interest for this educational activity, as applicable.

 

CME Accreditation Committee Disclosures:

Dr. Myriam Allende-Vigo reports that she does not have any relevant financial relationships with any commercial interests.

Dr. David S.H. Bell reports that he has received speaker honoraria from AstraZeneca, Boehringer Ingelheim GmbH, Eli Lilly and Company, and Novo Nordisk A/S, and consultant/speaker honoraria from Bristol-Myers Squibb and Takeda Pharmaceuticals North America, Inc.

Dr. Felice A. Caldarella reports that he has received research compensation from Boehringer Ingelheim GmbH and Eli Lilly and Company, speaker honoraria from Santarus, Inc., and speaker honoraria and research compensation from Novo Nordisk A/S.

Dr. Edward Chin reports that he does not have any relevant financial relationships with any commercial interests.

Dr. Stephen R. Crespin reports that he has received speaker honoraria from Bristol-Myers Squibb/AstraZeneca and Merck & Co., Inc.

Dr. Virginia A. LiVolsi reports that she has received histopathology consultant fees from Veracyte, Inc.

Dr. Dorothy S. Martinez reports that she does not have any relevant financial relationships with any commercial interests.

Dr. Andrew R. Reikes reports that his spouse is an employee and stockholder of GlaxoSmithKline plc.

Dr. Mushtaq A. Syed reports that he has received speaker honoraria from Novo Nordisk A/S. 

Dr. Joseph M. Tibaldi reports that he has received speaker honoraria from Daiichi-Sankyo company, Limited and Merck & Co., Inc., and speaker/consultant honoraria from Novo Nordisk A/S.

Dr. Dace L. Trence reports that she has received research grant support from Eli Lilly and Company and is a stockholder of Medtronic, Inc. and  sanofi-aventis U.S. LLC. 

 

Program Committee Disclosures:

*Dr. George Grunberger reports that he has received speaker honoraria and research support for his role as Investigator from Amylin Pharmaceuticals, Eli Lilly and Company, Novo Nordisk A/S, and Valeritas, Inc.; speaker honoraria from Amarin Corp. and Santarus Inc.; and research support for his role as Investigator from  GlaxoSmithKline plc and Janssen Pharmaceuticals, Inc.  He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Grunberger has an identified conflict of interest, and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Alan J. Garber reports that he has receivedAdvisory Board, consultant, and Speaker’s Bureau’s fees from Merck & Co., Inc., Novo Nordisk A/S, and Vivus Inc.; Advisory Board fees from Halozyme Therapeutics; Advisory Board and Speaker’s Bureau fees from Janssen Pharmaceuticals, Inc.; Advisory Board and consultant fees from Takeda Pharmaceuticals North America, Inc.; consultant and Speaker’s Bureau fees from Santarus Inc.; consultant fees from Tethys Bioscience and Viking Therapeutics; and Speaker’s Bureau fees from Eisai Co, Ltd. Dr. Garber has no identified conflicts of interest.

Dr. Jeffrey I, Mechanick reports that he has received Lecture/Program Development honoraria from Abbott Laboratories. Dr. Mechanick has no identified conflicts of interest.

Dr. Pasquale J. Palumbo reports that he does not have any relevant financial relationships with any commercial interests.  Dr. Palumbo has no identified conflicts of interest.

Dr. David S.H. Bell reports that he has received speaker honoraria from AstraZeneca, Boehringer Ingelheim GmbH, Eli Lilly and Company, and Novo Nordisk A/S, and speaker/consultant honoraria from Bristol-Myers Squibb and Takeda Pharmaceuticals North America, Inc.  Dr. Bell has no identified conflicts of interest.

Dr. Felice A. Caldarella reports that he has received speaker honoraria and research compensation from Novo Nordisk A/S, speaker honoraria from Santarus, and research compensation from Boehringer Ingelheim GmbH and Eli Lilly and Company.  Dr. Caldarella has no identified conflicts of interest.

Dr. Chris K. Guerin reports that he has received speaker honoraria from Eli Lilly and Company, Novo Nordisk A/S, and Santarus, Inc. Dr. Guerin has no identified conflicts of interest.

Dr. Yehuda Handelsman reports that he has received research grant support and speaker fees from Boehringer Ingelheim Gmbh and GlaxoSmithKline plc; research grant support from Conjuchem, LLC, Lexicon Pharmaceuticals, Inc., Takeda Pharmaceuticals Northa America, Inc., Tolerx, and Xoma; research grant support and speaker/consultant fees from Daiichi Sankyo Company, Limited and Novo Nordisk A/S; research grant support and consultant fees from Merck& Co. and sanofi-aventis U.S. LLC; consultant fees from Amarin Corp, Gilead, and Halozyme Therapeutics; and consultant/speaker fees from Amylin Pharmaceuticals Inc. Dr. Handelsman has no identified conflicts of interest.

Dr. Jennifer Hone reports that she does not have any relevant financial relationships with any commercial interests. Dr. Hone has no identified conflicts of interest.

Dr. Daniel L. Hurley reports that he does not have any relevant financial relationships with any commercial interests.  Dr. Hurley has no identified conflicts of interest.

Dr. Bethany A. Jackson reports that she does not have any relevant financial relationships with any commercial interests. Dr. Jackson has no identified conflicts of interest.

Dr. Armand A. Krikorian reports that he has received consultant fees from sanofi-aventis U.S. LLC. Dr. Krikorian has no identified conflicts of interest.

Dr. Etie S. Moghissi reports that she has received consultant honoraria from Amylin Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC, speaker honoraria from Boehringer Ingelheim GmbH, and speaker/consultant honoraria from Novo Nordisk A/S. Dr. Moghissi has no identified conflicts of interest.

Dr. Fernando Ovalle reports that he has received consultant/research fees from Bristol-Myers Squibb Company, Jannsen Pharmaceuticals, Inc., Medtronic, Inc., Novo Nordisk A/S, and sanofi-aventis U.S. LLC. Dr. Ovalle has not identified conflicts of interest.

Dr. Jill M. Paulson reports that she does not have any relevant financial relationships with any commercial interests.  Dr. Paulson has no identified conflicts of interest.

Dr. Paul D. Rosenblit reports that he has received speaker/teaching honoraria from Abbott Laboratories, Boehringer Ingelheim Gmbh, and Bristol-Myers Squibb; Advisory Board honoraria from Amarin Corp.; research grant support for his role as Principal Investigator from Andromeda Biotech Ltd., Daiichi Sankyo Company, Limited, and Eisai Co., Ltd.; research grant support for his role as Principal Investigator and speaker/teaching/Advisory Board honoraria from Eli Lilly and Company; research grant support for his role as Principal Investigator and speaker/teacher honoraria from AstraZeneca, GlaxoSmithKline plc,; and research grant support for his role as Principal Investigator and Advisory Board honoraria from Dexcom, Inc. Dr. Rosenblit has no identified conflicts of interest.

Dr. Cheryl R. Rosenfeld reports that she has received speaker honoraria and research grant support for her role as Principal Investigator from Amylin Pharmaceuticals Inc.; speaker honoraria, research grant support for her role as Principal Investigator, and consultant fees from Valeritas, and speaker honoraria from Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH/Eli  Lilly and Company,  and Genzyme. Dr. Rosenfeld has no identified conflicts of interest.

Dr. Stanley S. Schwartz reports that he has received Speaker’s Bureau honoraria from Boehringer Ingelheim GmbH, Novo Nordisk A/S, and Merck & Co., Inc; Advisory Board honoraria from Janssen Pharmaceuticals, Inc. and sanofi-aventis U.S. LLC; and Speaker Bureau and Advisory Board honoraria from AstraZeneca, Bristol Myers Squibb Company/Amylin Pharmaceuticals, Eli Lilly and Company, Santarus Inc. and Takeda Pharmaceuticals North America, Inc. Dr. Schwartz has no identified conflicts of interest.

Dr. Elliot Sternthal reports that he does not have any relevant financial relationships with any commercial interests.  Dr. Sternthal has no identified conflicts of interest.

Dr. Nancy S. Tarlin reports that she has received stock sanofi-aventis U.S. LLC. Dr Tarlin has no identified conflicts of interest.

Dr. Joseph M. Tibaldi reports that he has received speaker honoraria from Daiichi Sankyo Company, Limited, Janssen Pharmaceuticals, Inc., and Merck & Co., Inc., and speaker/consultant honoraria from Novo Nordisk A/S.  Dr. Tibaldi has no identified conflicts of interest.

Dr. Jeff Unger reports that he does not have any relevant financial relationships with any commercial interests.  Dr. Unger has no identified conflicts of interest.

 

 *Denotes individual is member of Program Committee and faculty.

 

Faculty Disclosures:

Dr. Vasdev Lohano reports that he has received speaker honoraria from Boehringer Ingelheim, Bristol-Myers Squibb/AstraZeneca, Eli Lilly and Company, and sanofi-aventis U.S. LLC. He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Lohano has an identified conflict of interest, and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Jahangir Cyrus reports that he has received speaker honoraria from AbbVie Inc, Boehringer Ingelheim GmbH/Eli Lilly and Company, and Novo Nordisk A/S.  He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Cyrus has an identified conflict of interest, and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Dr. Sathya Krishnasamy reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Krishnasamy has no identified conflicts of interest.

Dr. Sri Prakash Mokshagundam reports that he does not have any relevant financial relationships with any commercial interests.  He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Mokshagundam has no identified conflicts of interest.

Dr. Lal Tanwani reports that he has received speaker honoraria from AstraZeneca, Boehringer Ingelheim GmbH, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC.  He also reports that his presentation will not include discussion of any investigational or unlabeled use(s) of a product. Dr. Tanwani has an identified conflict of interest, and it has been resolved accordingly.  He has been advised by the AACE CME Accreditation Committee to base his presentation and recommendations on the best available, preferably published evidence/information.

Ms. Beth Ackerman reports that she does not have any relevant financial relationships with any commercial interests. She also reports that her presentation will not include discussion of any investigational or unlabeled use(s) of a product. Ms. Ackerman has no identified conflicts of interest.

Corporate Support

AACE would like to acknowledge the following companies that have provided support for this educational activity.

Boehringer Ingelheim Pharmaceuticals, Inc.,

which was made possible, in part, through collaboration with Eli Lilly and Company

Novo Nordisk Inc.

sanofi-aventis U.S.

*Accurate at time of posting.

Physician Credit

The American Association of Clinical Endocrinologists (AACE) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Association of Clinical Endocrinologists (AACE) designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credit(s)™.

Physicians should only claim credit commensurate with the extent of their participation in the activity.

 

Nursing Credit

This educational activity for 4.5 contact hours is provided by Postgraduate Institute for Medicine.

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Postgraduate Institute for Medicine is approved by the California Board of Registered Nursing, Provider Number 13485 for 4.5 contact hours.

There is no fee for this educational activity.

For information about ACPE and ANCC accreditation, please contact Postgraduate Institute for Medicine at (303) 799-1930 or information@primed.com.

Pharmacist Credit

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Postgraduate Institute for Medicine designates this continuing education activity for 4.5 contact hour(s) (0.45 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0809-9999-12-356-L01-P)

Type of Activity: Knowledge-Based

For information about ACPE and ANCC accreditation, please contact Postgraduate Institute for Medicine at (303) 799-1930 or information@primed.com  

Location

The Seelbach Hilton Hotel - Medallion Ballroom

500 Fourth Street

Louisville, KY  40202 

Register
Program Fee
There is no registration fee to attend this meeting. We do request that you pre-register by completing this form. AACE Membership is NOT required to attend this program.
Registration Type
Contact Information
Cancellation Policy
AACE reserves the right to cancel this course based on enrollment or conditions beyond our control. In the case of program cancellation, each pre-registrant will be notified by phone and/or email. AACE is not responsible for any costs incurred due to program cancellation, such as airline or hotel penalties.
E-mail Disclaimer
By entering your email address, you agree that your email address can be used for future correspondence from the American Association of Clinical Endocrinologists. This information would include, but is not limited to certifications, program information and future advertisements.
Finish Registration
A Printed Syllabus will NOT be distributed for this activity.
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.